Another IPO! TVAX Seeks $40M To Fund Cancer Immunotherapy
By Marie Powers
Wednesday, November 9, 2011
Cancer immunotherapy firm TVAX Biomedical Inc. became the latest biotech to line up this year for an initial public offering, filing an S-1 on Monday and seeking to raise $40 million.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.